Application of ABCA13 cytokine to preparation of hepatic failure treatment drug

A technology of liver failure and cytokines, applied in the field of molecular medicine, biomedicine, and clinical medicine, can solve problems such as the shortage of liver donors and the death of patients

Inactive Publication Date: 2019-09-27
ZHEJIANG UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But due to a severe shortage of donor livers, a large num

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ABCA13 cytokine to preparation of hepatic failure treatment drug
  • Application of ABCA13 cytokine to preparation of hepatic failure treatment drug
  • Application of ABCA13 cytokine to preparation of hepatic failure treatment drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: Injection containing ABCA13 cytokines treats a large animal (young pig) model of liver failure

[0043] Animal model: 30 male Chinese young pigs (8-10 kg) were randomly divided into two groups, 15 in each group. Each young pig was injected with D-gal 1.5g / kg in the jugular vein to create a liver failure model.

[0044] Test group: Multiple intravenous injections of ABCA13 injection at fixed time points after D-gal injection, dose: 10ml / kg, twice a day.

[0045] Control group: inject the same amount of normal saline without ABCA13.

[0046] Neither the control group nor the experimental group received other drug treatment.

[0047] figure 1 It is a schematic diagram of the survival time curves of the young pigs of the experimental group and the control group, showing the survival rate of the young pigs of the experimental group and the control group. The results showed that the 3-day survival rate of young pigs in the treatment group containing ABCA13 c...

Embodiment 2

[0048] Example 2: A small animal (rat) model of liver failure treated by freeze-dried powder injection containing ABCA13 cytokine

[0049] Animal model: 100 male rats (200-250 g) were randomly divided into two groups, 50 in each group. Each rat was intraperitoneally injected with D-gal 1.5g / kg to make a liver failure model. The ABCA13 freeze-dried powder and water for injection are prepared into a suspension.

[0050] Experimental group: 4ml of ABCA13 freeze-dried powder suspension was injected intraperitoneally at a fixed time point after D-gal injection, twice a day.

[0051] Control group: inject the same amount of normal saline without ABCA13.

[0052] Both the control group and the experimental group received no other drug treatment.

[0053] figure 2 Schematic diagram of the survival time curves of rats in the experimental group and the control group, figure 2The survival rates of rats in the experimental group and the control group were shown: the results showed ...

Embodiment 3

[0054] Embodiment 3: The suspension containing ABCA13 cytokine treats the rabbit model of liver failure

[0055] Animal model: 40 adult male rabbits (2000-2500 g) were randomly divided into two groups, 20 in each group. Each rabbit was intramuscularly injected with D-gal 1.5g / kg to make a liver failure model.

[0056] Test group: intramuscular injection of 20 ml of ABCA13 suspension at fixed time points after D-gal injection, twice a day.

[0057] Control group: inject the same amount of normal saline without ABCA13.

[0058] Both the control group and the experimental group received no other drug treatment.

[0059] image 3 It is a schematic diagram of the survival time curves of rabbits in the experimental group and the control group, image 3 The survival rate of rabbits in the experimental group and the control group is shown: the results show that the survival rate of the rabbits in the ABCA13 treatment group is 90% at 1 day and 80% at 7 days, while the survival rate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of an ABCA13 cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the ABCA13 cytokine, and the drug is in the form of an injection, a freeze-dried powder injection or a suspension. ABCA13 is one of ABCA superfamily members, mediates transmembrane transport of lipids and adjusts metabolic disorders such as hepatocyte steatosis and the like in the hepatic failure process, and ABCA13 is functionally related with mesenchymal stem cells and has a treatment effect for promoting liver repair. According to the application of the ABCA13 cytokine to preparation of the hepatic failure treatment drug, biochemical indexes of a patient can be remarkably improved, bilirubin level and transaminase are reduced, coagulation function and albumin level are improved, fatal complications such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome are prevented, the survival time is remarkably prolonged, and the survival rate is increased.

Description

technical field [0001] The invention belongs to the fields of clinical medicine, molecular medicine and biomedicine, and is a new technology for treating liver failure with ABCA13 cytokine series drugs, specifically, the application of ABCA13 cytokine in the preparation of medicaments for treating liver failure. Background technique [0002] Liver failure is a kind of disease caused by extensive necrosis of the liver caused by various reasons. Except for orthotopic liver transplantation, there is currently no specific treatment. However, due to the severe shortage of donor livers, a large number of patients died while waiting for liver transplantation. Clarifying the pathogenesis of liver failure and early treatment targeting the mechanism can effectively block the progression of the disease and reduce the mortality rate, which is of great significance to the treatment of liver failure. [0003] The ATP-binding cassette protein superfamily is one of the largest membrane pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/19A61P1/16
CPCA61K38/19A61P1/16
Inventor 李君陈新李江梁茜李佳琪石东燕
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap